Medicine Grade 99% Purity Avanafil Manufacturer From China 330784-47-9 with fast

Medicine Grade 99% Purity Avanafil Manufacturer From China 330784-47-9

1. Basic Information:
Avanafil
CAS No.: 330784-47-9
MF: C23H26ClN7O3
MW: 483.95
Grade: USP standard

Minimum Order Quantity: 10GRAMS
Payment: MoneyGram; Western Union; Bitcoin; Bank Transfer
Delivery: By Express
Shipping Time: 5 Workdays

More Information:
Avanafil comes as a tablet to take by mouth. It is usually taken with or without food as needed, about 30 minutes before sexual activity. Do not take avanafil more often than once in 24 hours. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take avanafil exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

COA of Avanafil

Avanafil is a pde5 inhibitor approved for erectile dysfunction by FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina.Other similar drugs are tadalafil and vardenafil.The advantage of avanafil is that it has very fast onset of action compared with other pde5 inhibitors.It is absorbed quickly, reaching a maximum concentration in about 30-45 minutes.About two-thirds of the participants were able to engage in sexual activity within 15 minutes.

It is a development of the phosphodiesterase type 5 inhibitors, for the treatment of male sexual dysfunction, at present in the America, EU and Japan have completed phase II clinical trials, phase III clinical trials will start. The product is composed of Japanese Tanabe Pharma Company and VIVUS company development. In addition to oral dosage forms, VIVUS company is also developing Avanafil urethral administration, for not responding to oral dosage forms of patients.

Avanafil is a potent, highly selective phosphodiesterase 5 inhibitor, in vitro experiments showed that the selectivity of phosphodiesterase 5 stronger than . The compound dear compliance weak against other phosphodiesterase, and effect of adenosine receptor decreased, suggesting that the cardiovascular effects of avanafil should be weaker than .

Pre clinical study showed that avanafil and organic nitrate drugs taken in combination to reduce its on blood pressure was significantly weaker than and nitrate drugs with clothes. Moreover, avanafil inhibition of phosphodiesterase 6 is very weak, the relevant visual disturbance suppression may the enzyme phosphodiesterase 5 inhibitor induced and other.



More Products: